First-pass extracted concept

cancer nanomedicine

Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

Title: Cancer nanomedicine: progress, challenges and opportunities
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1example modalitysupports2016Source 1DOIPubMed

The topic scope includes exemplar nanomedicine modalities already used or tested clinically, including albumin-bound paclitaxel.

Quoted textsource-backed
The anchor article is a 2017 Nature Reviews Cancer review on cancer nanomedicine that emphasizes three recurring enrichment themes ... (3) exemplar nanomedicine modalities already used or tested clinically, such as albumin-bound paclitaxel.
Claim 2mechanistic themesupports2016Source 1DOIPubMed

The anchor review emphasizes biological delivery constraints in tumors, especially the enhanced permeability and retention framework and its limitations.

Quoted textsource-backed
The anchor article is a 2017 Nature Reviews Cancer review on cancer nanomedicine that emphasizes three recurring enrichment themes also strongly represented in the surrounding literature: (1) biological delivery constraints in tumors, especially the enhanced permeability and retention (EPR) framework and its limitations
Claim 3review scopesupports2016Source 1DOIPubMed

The review addresses progress, challenges, and opportunities in cancer nanomedicine.

Quoted textsource-backed
Cancer nanomedicine: progress, challenges and opportunities
Claim 4translational themesupports2016Source 1DOIPubMed

The anchor review emphasizes translational and clinical-manufacturing barriers in cancer nanomedicine.

Quoted textsource-backed
The anchor article is a 2017 Nature Reviews Cancer review on cancer nanomedicine that emphasizes three recurring enrichment themes also strongly represented in the surrounding literature: ... (2) translational and clinical-manufacturing barriers